Subsequent Events - Additional Information (Detail)	1 Months Ended		12 Months Ended
	Feb. 29, 2016 USD ($)	Aug. 31, 2015 USD ($) Antibody shares	Dec. 31, 2015	Mar. 02, 2016 USD ($) Antibody
TNK Therapeutics Inc [Member] | Membership Interest Purchase Agreement [Member] | CARgenix Holding LLC [Member]
Subsequent Event [Line Items]
Cash payment		$ 100,000
Minimum qualified financing		$ 50,000,000
Purchase agreement terms, description			In the event a Qualified Financing does not occur by March 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by March 31, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Members shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances.
Aggregate common stock to be issued, shares | shares		309,917
TNK Therapeutics Inc [Member] | Stock Purchase Agreement [Member] | B D L Products Inc [Member]
Subsequent Event [Line Items]
Cash payment		$ 100,000
Purchase agreement terms, description			In the event a Qualified Financing does not occur by March 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by March 31, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances.
Aggregate common stock to be issued, shares | shares		309,917
TNK Therapeutics Inc [Member] | Class A [Member] | Membership Interest Purchase Agreement [Member] | CARgenix Holding LLC [Member]
Subsequent Event [Line Items]
Common stock to be issued, value		$ 6,000,000
TNK Therapeutics Inc [Member] | Class A [Member] | Stock Purchase Agreement [Member] | B D L Products Inc [Member]
Subsequent Event [Line Items]
Common stock to be issued, value		6,000,000
Mabtech Limited [Member] | CHINA [Member]
Subsequent Event [Line Items]
Initial payment for license agreement		10,000,000
Licensing agreement, additional amounts payable		$ 190,000,000
Licensing agreement, additional amounts payable, term		4 years
Number of monoclonal antibodies | Antibody		4
Subsequent Event [Member] | ImmuneOncia Therapeutics, LLC [Member]
Subsequent Event [Line Items]
Initial investment				$ 10,000,000
Number of monoclonal antibodies | Antibody				2
Ownership percentage in joint venture				49.00%
Subsequent Event [Member] | Mabtech Limited [Member] | CHINA [Member]
Subsequent Event [Line Items]
Initial payment for license agreement	$ 10,000,000
Licensing agreement, additional amounts payable	$ 180,000,000
Licensing agreement, additional amounts payable, term	4 years
Subsequent Event [Member] | Yuhan Corporation [Member] | ImmuneOncia Therapeutics, LLC [Member]
Subsequent Event [Line Items]
Ownership percentage in joint venture				51.00%